Who are olanzapine + fluoxetine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Olanzapine-Fluoxetine Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olanzapine-fluoxetine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

olanzapine + fluoxetine — Competitive Intelligence Brief

olanzapine + fluoxetine (olanzapine + fluoxetine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic + SSRI combination. Area: Psychiatry.

marketed Atypical antipsychotic + SSRI combination Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

olanzapine + fluoxetine (olanzapine + fluoxetine) — University of Florida. Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
olanzapine + fluoxetine TARGET	olanzapine + fluoxetine	University of Florida	marketed	Atypical antipsychotic + SSRI combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
Olanzapine-Fluoxetine Combination	Olanzapine-Fluoxetine Combination	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + SSRI combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic + SSRI combination class)

All India Institute of Medical Sciences, Bhubaneswar · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olanzapine + fluoxetine — Competitive Intelligence Brief. https://druglandscape.com/ci/olanzapine-fluoxetine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab